Vitamin K2 for Men: Cardiovascular Calcification Prevention and Bone Health

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning any supplement. Dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.

By VFM Research Desk | Last verified: July 2026

Vitamin K2 (Menaquinone): Cardiovascular Protection and Bone Activation for Men

The Quick Answer

Vitamin K2 activates two critical proteins—Matrix GLA Protein (MGP) and osteocalcin—that direct calcium deposition into bone while preventing arterial calcification. The Rotterdam Study demonstrated that high K2 intake correlated with a 50% reduction in cardiovascular mortality in men over 55. Research-supported forms include MK-7 (100–200 mcg daily) and MK-4 (45mg pharmaceutical dose used in Japanese bone studies). Evidence is strong for cardiovascular protection, moderate for bone density, and preliminary for testosterone support.

What It Is: The Master Calcium Trafficker

Vitamin K2 is a fat-soluble vitamin and member of the menaquinone family—a group of compounds produced by bacterial fermentation rather than plants. Unlike vitamin K1 (phylloquinone), which is abundant in leafy greens and primarily involved in blood clotting, K2 has a long hydrocarbon tail that allows it to distribute throughout the body and accumulate in tissues like bone, vascular walls, and reproductive organs.

K2 exists in two primary supplement forms: MK-4 (menaquinone-4, short half-life of 6–8 hours) and MK-7 (menaquinone-7, half-life of approximately 72 hours). MK-4 is derived from animal products and is the form used in high-dose pharmaceutical studies from Japan. MK-7 comes from fermented foods like natto (fermented soybeans) and is increasingly available in supplements. The longer half-life of MK-7 makes it suitable for daily supplementation without multiple dosing windows.

The Research: What K2 Does for Men’s Health

Cardiovascular Protection Through Arterial Calcification Prevention

The strongest evidence for K2 in men comes from the Rotterdam Study, a prospective cohort of over 4,800 men and women aged 55+. Researchers tracked dietary K2 intake and cardiovascular outcomes over 7–10 years. Men in the highest quartile of K2 intake showed a 50% reduction in cardiovascular death compared to the lowest quartile. The mechanism is well-established: K2 activates Matrix GLA Protein (MGP), a powerful inhibitor of vascular calcification. Without adequate K2, calcium deposits in arteries (atherosclerotic calcification), reducing arterial elasticity and increasing CVD risk. This is particularly relevant for men over 50, who experience higher cardiovascular mortality than women and face aggressive atherosclerosis progression.

Additional evidence: Multiple observational studies link high K2 intake to lower arterial calcium scores on imaging. Experimental models show that K2 deficiency accelerates vascular calcification in animals fed high-calcium diets. Evidence level: Strong (observational cohort).

Bone Mineral Density and Fracture Risk

Japanese researchers have extensively studied K2 for bone health, particularly MK-4 at pharmaceutical doses (45mg daily). These trials showed K2 activates osteocalcin, a bone matrix protein essential for calcium binding and mineralization. Studies in postmenopausal women (and extrapolated to aging men) demonstrate that 45mg MK-4 daily increased bone mineral density and reduced vertebral fracture incidence. However, this dose is substantially higher than typical supplement formulations.

The mechanism: K2-dependent proteins act as “calcium attractors.” Osteocalcin, when activated by K2, preferentially directs calcium into bone mineral matrix rather than allowing it to circulate and calcify soft tissues. This is why K2 synergizes critically with vitamin D3: D3 increases dietary calcium absorption, but without K2, excess calcium may deposit in arteries rather than bone. Men concerned about osteoporosis risk (particularly those over 60 or on long-term glucocorticoids) may benefit from combined K2+D3 supplementation. Evidence level: Moderate to Strong (RCT and observational data, primarily in Asian populations).

Testosterone Support: Preliminary Evidence

Animal studies suggest MK-4 may stimulate testosterone synthesis in Leydig cells of the testes via PKA pathway activation. One Japanese in vitro study showed K2-dependent protein activity correlated with testosterone production in cultured testicular cells. However, human clinical trials are lacking. No RCT has definitively shown that K2 supplementation raises testosterone levels in men. This benefit should be considered preliminary and not a primary reason to supplement K2. If pursued for testosterone support, K2 should be part of a broader strategy (vitamin D3, zinc, exercise) rather than a standalone agent. Evidence level: Preliminary (animal and in vitro only).

Dental Remineralization: Moderate Evidence

Emerging research suggests K2 may support enamel remineralization and jawbone density through osteocalcin activation. Studies are limited and primarily observational, but K2’s role in bone metabolism suggests potential for periodontal health. This is a secondary benefit and should not drive purchasing decisions independently. Evidence level: Moderate (preliminary human evidence).

Evidence Summary Table

The Dose Math: Clinical Doses vs. What You’re Actually Getting

This is where K2 supplementation becomes tricky. There is no established RDA for vitamin K2 in men (the RDA only covers K1 for clotting function). However, research-supported doses vary dramatically by form:

MK-7 (preferred for daily supplementation): Most commercial supplements contain 100–200 mcg MK-7 per dose. The Rotterdam Study suggested cardiovascular benefit at high dietary intakes, correlating to roughly 50–100+ mcg daily from food sources. Most supplement doses of 100–200 mcg MK-7 are aligned with levels associated with cardiovascular protection in observational research. One dose daily is typical due to the 72-hour half-life.

MK-4 (pharmaceutical-grade bone research): Japanese clinical trials used 45mg daily—a pharmaceutical dose far exceeding typical supplements. Most MK-4 supplements contain only 5–10mg per capsule. To reach the 45mg dose used in bone density studies, you would need 5–9 capsules daily of a standard product. The short 6–8 hour half-life also means MK-4 requires multiple daily doses to maintain steady-state levels. This is impractical for most men.

The practical takeaway: If your primary goal is cardiovascular protection (the strongest evidence), MK-7 100–200 mcg daily likely delivers a therapeutic dose. If you’re targeting bone density, MK-7 at 100–200 mcg daily may provide benefit, but reaching the pharmaceutical 45mg MK-4 dose used in peak bone trials requires either finding a specialized pharmaceutical-grade MK-4 product or accepting that standard supplements deliver subtherapeutic doses for this specific benefit. Combining K2 with vitamin D3 (2,000–4,000 IU daily) is synergistic: D3 increases calcium availability; K2 directs it appropriately.

Forms & Bioavailability: Which K2 Should You Buy?

MK-7 (menaquinone-7): Superior for daily supplementation. Derived from natto fermentation. Longer half-life (≈72 hours) allows once-daily dosing. Studies show MK-7 distributes effectively to extrahepatic tissues (bone, vascular walls). Most bioavailable form for cardiovascular and general health purposes. Typical dose: 100–200 mcg once daily with a fat-containing meal (K2 is fat-soluble).

MK-4 (menaquinone-4): Preferred in Asian pharmaceutical-grade bone research due to higher doses used. Found in animal products (eggs, grass-fed dairy, hard cheeses). Short half-life requires multiple daily doses to maintain steady-state. Standard supplements underdose relative to clinical trials. If you choose MK-4, look for products providing at least 15–30mg per dose and consider 2–3 doses daily to approximate therapeutic levels. MK-4 may accumulate more efficiently in certain tissues than MK-7 (though evidence is mixed).

MK-5, MK-8, MK-9, etc.: Other menaquinone forms exist but lack clinical trial support in humans. Stick with MK-7 or MK-4.

Absorption tip: K2 is fat-soluble; take with dietary fat (olive oil, nuts, fatty fish, avocado) for optimal absorption. Some formulas include coconut or MCT oil for this reason—this is a legitimate formulation choice, not marketing.

Who Should Consider K2 and Who Should Avoid It

Good Candidates for K2 Supplementation

• Men 50+: Cardiovascular calcification risk increases sharply. K2 addresses a specific mechanism (MGP activation) not covered by standard statins or antihypertensives.
• Men on high-dose vitamin D3: If taking 4,000+ IU D3 daily, K2 becomes important to direct excess calcium toward bone rather than arteries.
• Men with osteoporosis risk: Age 60+, family history of fracture, long-term glucocorticoid use, or sedentary lifestyle. Combined K2+D3 is evidence-supported.
• Men with low dietary K2 intake: Those avoiding fermented foods, grass-fed dairy, and hard cheeses. Dietary K2 is limited in typical Western diets (mainly natto, certain cheeses, some fortified products).

Who Should Avoid or Caution with K2

• Men on warfarin or other vitamin K-antagonist anticoagulants: K2 can reduce warfarin efficacy by increasing clotting factors. This is a contraindication. Consult your prescribing physician before starting K2. (Note: DOACs like apixaban or dabigatran are not K-dependent and are generally compatible with K2, though your doctor should confirm.)
• Men with thrombotic tendency or unprovoked DVT/PE history: K2 increases clotting factor activation; caution is warranted.
• Men on antibiotics that deplete gut bacteria: K2-producing gut bacteria may be disrupted. Time supplementation appropriately (after antibiotic course concludes).

For specific questions about K2 compatibility with your medications (particularly blood thinners, statins, or PDE5 inhibitors for ED), see our guide to supplement and blood thinner interactions.

Safety & Side Effects: What’s Known at Clinical Doses

Side effect profile: K2 is well-tolerated at clinical doses. No serious adverse events have been reported in RCTs. Occasional mild GI upset or headache, typically resolving within days.

Interactions with medications:

• Warfarin/vitamin K antagonists: Direct contraindication. K2 increases prothrombin time (PT), reducing anticoagulant effect. DO NOT combine without medical supervision.
• DOACs (apixaban, rivaroxaban, dabigatran): Generally safe; K2 does not significantly affect DOAC efficacy (these anticoagulants operate through Factor Xa or IIa inhibition, not K-dependent pathways). Confirm with your prescriber.
• Statins: No significant interaction. Some evidence suggests K2 supports statin therapy for cardiovascular protection (complementary mechanisms).
• Bisphosphonates (osteoporosis drugs): No direct interaction, but timing may matter—take K2 separately by 2+ hours if co-prescribing.

Upper tolerable intake level (UL): No UL has been formally established for K2 by the Institute of Medicine, suggesting a wide margin of safety at supplemental doses. Traditional use in fermented food cultures shows no toxicity at dietary levels.

Internal Synergies & Strategic Pairing

K2 works best alongside vitamin D3 for bone and cardiovascular health. D3 increases intestinal calcium absorption; K2 ensures that calcium is directed into bone and away from arteries. If supplementing with both, typical effective doses are: D3 2,000–4,000 IU daily + K2 100–200 mcg (MK-7) daily or 15–45mg (MK-4) daily, depending on your health goals and the form available.

For men interested in cardiovascular supplement strategies, K2 addresses calcium trafficking—a distinct benefit from omega-3s (inflammation), CoQ10 (mitochondrial support), or magnesium (vasodilation). Using multiple mechanisms creates redundancy and lower individual doses.

The Bottom Line

The evidence for K2 in men is strongest for cardiovascular protection through arterial calcification prevention. The Rotterdam Study’s 50% reduction in cardiovascular mortality in high-K2-intake men is substantial and mechanistically sound. For men 50+, particularly those on high-dose D3 or with cardiovascular risk factors, MK-7 supplementation (100–200 mcg daily) represents a reasonable, well-tolerated investment in vascular health with minimal side effects.

Bone density benefits are real but typically require either combined D3+K2 therapy or (for maximum bone effect) pharmaceutical-grade MK-4 at 45mg daily—a dose far exceeding standard supplement formulations. Testosterone support remains theoretical and should not drive purchasing decisions. The critical caveat: men on warfarin or other vitamin K-antagonist drugs must avoid K2 entirely without medical clearance.

Practical recommendation: Start with MK-7 100–200 mcg daily with a fat-containing meal if you’re 50+, on high-dose D3, or concerned about arterial calcification. Pair it with vitamin D3 for synergistic bone and cardiovascular support. Reassess after 6–12 months based on cardiovascular markers (CAC scoring) or bone density scans if available.